Loading stock data…
$1.29-0.11 (-7.86%)
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. in the Healthcare sector is trading at $1.29 with a market capitalization of $553M. Wall Street consensus targets $9.00 (9 analysts), implying a +597.7% move over the next 12 months. The stock is currently near its 52-week low of $1.04, remaining 35.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.64M | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.92M↓ | -$46.09M↓ | -$42.40M↑ | -$44.90M↑ | -$54.44M |
| Net Income | -$42.68M↓ | -$42.61M↓ | -$38.81M↑ | -$41.40M↑ | -$50.94M |
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CA...